222 related articles for article (PubMed ID: 22621216)
1. The pharmacogenetics of β-adrenergic receptor antagonists in the treatment of hypertension and heart failure.
Chan SW; Hu M; Tomlinson B
Expert Opin Drug Metab Toxicol; 2012 Jul; 8(7):767-90. PubMed ID: 22621216
[TBL] [Abstract][Full Text] [Related]
2. beta-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure.
Terra SG; Pauly DF; Lee CR; Patterson JH; Adams KF; Schofield RS; Belgado BS; Hamilton KK; Aranda JM; Hill JA; Yarandi HN; Walker JR; Phillips MS; Gelfand CA; Johnson JA
Clin Pharmacol Ther; 2005 Mar; 77(3):127-37. PubMed ID: 15735607
[TBL] [Abstract][Full Text] [Related]
3. Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics.
Sehrt D; Meineke I; Tzvetkov M; Gültepe S; Brockmöller J
Pharmacogenomics; 2011 Jun; 12(6):783-95. PubMed ID: 21599570
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetics of beta1-adrenergic receptors in heart failure and hypertension.
Mialet-Perez J; Liggett SB
Arch Mal Coeur Vaiss; 2006 Jun; 99(6):616-20. PubMed ID: 16878723
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.
Zineh I; Beitelshees AL; Gaedigk A; Walker JR; Pauly DF; Eberst K; Leeder JS; Phillips MS; Gelfand CA; Johnson JA
Clin Pharmacol Ther; 2004 Dec; 76(6):536-44. PubMed ID: 15592325
[TBL] [Abstract][Full Text] [Related]
6. beta1-Adrenergic receptor polymorphisms influence the response to metoprolol monotherapy in patients with essential hypertension.
Liu J; Liu ZQ; Yu BN; Xu FH; Mo W; Zhou G; Liu YZ; Li Q; Zhou HH
Clin Pharmacol Ther; 2006 Jul; 80(1):23-32. PubMed ID: 16815314
[TBL] [Abstract][Full Text] [Related]
7. [Genetic polymorphisms in drug metabolizing enzymes--impact on treatment with beta-blockers].
Wuttke H; Rau T; Eschenhagen T
Dtsch Med Wochenschr; 2004 Apr; 129(15):831-5. PubMed ID: 15054690
[No Abstract] [Full Text] [Related]
8. Pharmacogenetics of beta-blockers.
Shin J; Johnson JA
Pharmacotherapy; 2007 Jun; 27(6):874-87. PubMed ID: 17542770
[TBL] [Abstract][Full Text] [Related]
9. Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in beta-blocker users.
Bijl MJ; Visser LE; van Schaik RH; Kors JA; Witteman JC; Hofman A; Vulto AG; van Gelder T; Stricker BH
Clin Pharmacol Ther; 2009 Jan; 85(1):45-50. PubMed ID: 18784654
[TBL] [Abstract][Full Text] [Related]
10. Chronic heart failure: beta-blockers and pharmacogenetics.
Azuma J; Nonen S
Eur J Clin Pharmacol; 2009 Jan; 65(1):3-17. PubMed ID: 18839161
[TBL] [Abstract][Full Text] [Related]
11. [Beta-adrenergic receptor blockers in clinical practice].
Czuriga I; Edes I
Orv Hetil; 2004 Sep; 145(38):1951-60. PubMed ID: 15535106
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of disease: beta-adrenergic receptors--alterations in signal transduction and pharmacogenomics in heart failure.
Feldman DS; Carnes CA; Abraham WT; Bristow MR
Nat Clin Pract Cardiovasc Med; 2005 Sep; 2(9):475-83. PubMed ID: 16265588
[TBL] [Abstract][Full Text] [Related]
13. Synergistic polymorphisms of beta1 and alpha2C-adrenergic receptors and the influence on left ventricular ejection fraction response to beta-blocker therapy in heart failure.
Lobmeyer MT; Gong Y; Terra SG; Beitelshees AL; Langaee TY; Pauly DF; Schofield RS; Hamilton KK; Herbert Patterson J; Adams KF; Hill JA; Aranda JM; Johnson JA
Pharmacogenet Genomics; 2007 Apr; 17(4):277-82. PubMed ID: 17496726
[TBL] [Abstract][Full Text] [Related]
14. [The clinical pharmacology of beta-adrenoblockers].
Sychev DA; Ramenskaia GV; Ignat'ev IV; Smirnikhina SA; Kazakov RE; Kukes VG
Klin Med (Mosk); 2006; 84(3):4-9. PubMed ID: 16758913
[TBL] [Abstract][Full Text] [Related]
15. Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics.
Kirchheiner J; Heesch C; Bauer S; Meisel C; Seringer A; Goldammer M; Tzvetkov M; Meineke I; Roots I; Brockmöller J
Clin Pharmacol Ther; 2004 Oct; 76(4):302-12. PubMed ID: 15470329
[TBL] [Abstract][Full Text] [Related]
16. Nebivolol: a third-generation beta-blocker for hypertension.
Cheng JW
Clin Ther; 2009 Mar; 31(3):447-62. PubMed ID: 19393838
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenomics of heart failure.
Lymperopoulos A; French F
Methods Mol Biol; 2014; 1175():245-57. PubMed ID: 25150872
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetics and heart failure: a convergence with carvedilol.
Meadowcroft AM; Williamson KM; Patterson JH; Pieper JA
Pharmacotherapy; 1997; 17(4):637-9. PubMed ID: 9250542
[No Abstract] [Full Text] [Related]
19. Pharmacogenomics of heart failure: a systematic review.
Mottet F; Vardeny O; de Denus S
Pharmacogenomics; 2016 Nov; 17(16):1817-1858. PubMed ID: 27813451
[TBL] [Abstract][Full Text] [Related]
20. Models for evaluating the pharmacokinetics and pharmacodynamics for β-blockers.
Höcht C; Bertera FM; Del Mauro JS; Taira CA
Expert Opin Drug Metab Toxicol; 2014 Apr; 10(4):525-41. PubMed ID: 24593316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
